Mobile Site ›

Print Page Email Page
Print Friendly View

Unit Code 80919:
Drug Abuse Survey with Confirmation, Evaluation 3, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting drug abuse involving amphetamines, barbiturates,

benzodiazepines, cocaine, marijuana metabolite, opiates, and

phencyclidine (PCP).

 

This test is intended to be used in a setting where the test results

can be used definitively to make a diagnosis.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

#80919 "Drug Abuse Survey with Confirmation, Evaluation 3, Urine"

was designed to test for and confirm (by gas chromatography-mass

spectrometry [GC-MS]) the most common classes of drugs of abuse.

 

This test uses the screening technique described under #8248 "Drug

Abuse Survey, Urine," which involves immunologic testing for drugs

by class. All positive screening results are confirmed by GC-MS

and quantitated before a positive result is reported.

 

This test represents the coupling of #8248 "Drug Abuse Survey,

Urine" with an automatic confirmation of all positive results by the

definitive assay available and described elsewhere (e.g., #8257

"Amphetamines, Urine").

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Screening cutoff concentrations

      Amphetamines:  500 ng/mL

      Barbiturates:  200 ng/mL

      Benzodiazepines:  200 ng/mL

      Cocaine (benzoylecgonine - cocaine metabolite):  300 ng/mL

      Opiates:  300 ng/mL

      Phencyclidine:  25 ng/mL

      Tetrahydrocannabinol carboxylic acid:  20 ng/mL

This report is intended for use in clinical monitoring or

management of patients. It is not intended for use in

employment-related testing.

Interpretation Provides information to assist in interpretation of the test results

A positive result indicates that the patient has used the drug(s)

detected in the recent past. See "Quick Reference Guide" in

Special Instructions for estimated windows of detection

(the length of time after last use that drug may be present in the

urine). See individual tests (e.g., #8257 "Amphetamines, Urine")

for more information.

 

For general information about drug testing, see

"Drug Testing: An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse"

at www.MayoMedicalLaboratories.com.

 

Creatinine and specific gravity are measured as indicators of

specimen dilution.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Not intended for use in employment-related testing.

 

The test does not screen for drug classes other than those listed

above. More comprehensive screening is available using the

plasma or urine drug screens (#8421 "Drug Screen, Prescription/OTC,

Plasma" or #88760 "Drug Screen, Prescription/OTC, Urine").

 

For situations where chain-of-custody is required, a Chain-of-

Custody Kit (Supply T282) is available.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

Porter WF, Moyer TP: Clinical toxicology. In Tietz Textbook of

Clinical Chemistry. 4th edition. Edited by CA Burtis, ER Ashwood.

Philadelphia, WB Saunders Company, 1993, pp 1155-1235

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

• Adulterant Survey Algorithm 
• Quick Reference Guide